Rigel Pharmaceuticals (RIGL) Receivables - Other (2025 - 2026)
Rigel Pharmaceuticals' quarterly Receivables - Other came in at $1.0 million in Q1 2026, up 1654.39% year-on-year from $57000.0 in Q1 2025, and up 11.11% quarter-over-quarter from $900000.0 in Q4 2025.
Rigel Pharmaceuticals has reported Receivables - Other for 2 years, with the latest figure at $1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Other rose 1654.39% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 1654.39% YoY), and the FY2025 full-year result was $900000.0, changed N/A from the prior year.
- Receivables - Other for Q1 2026 stood at $1.0 million, up from $900000.0 in the prior quarter.
- The five-year high for Receivables - Other was $1.0 million in Q1 2026, with the low at $57000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 900,000.00 |
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |